Nabil Saba, MD
@DrNabilSaba
Followers
1K
Following
2K
Media
49
Statuses
479
Director of Head & Neck Oncology, Vice Chair at @WinshipAtEmory. Medical Oncologist; H&N cancer expert. Opinions=my own https://t.co/CXZsMJ6Sg2
Atlanta, GA
Joined October 2014
0
1
0
RT @NikkiSchmittMD: Excited to share our study of RT + IAP antagonist tolinapant in cis-ineligible HNSCC, showing safety/feasibility and pr….
0
2
0
RT @eaonc: “The results support chemotherapy before surgery as an effective intervention to improve preservation of vital organs, bone, and….
0
3
0
Excellent presentation by @ConorSteuerMD covering reversal of immunosuppressive environment with #pepinemab in #HNCA @ASCO CSS @WinshipAtEmory @EmoryUniversity @LesinskiLab @Vaccinex @NikkiSchmittMD
0
2
18
RT @UPMCHillmanCC: Planning your day for @ASCO? Join @DanZandberg for an oral presentation on cSCC. #ASCO25 @UPMCPhysicianEd @UPMCnews http….
0
3
0
Great #ASCO25 discussion by @anantm around AI based prediction models in #HNCA @WinshipAtEmory @EmoryUniversity @ASCO @MedAIEmory
1
3
16
RT @eaonc: EA3231 is a phase 3 #ClinicalTrial of targeted therapy vs. chemotherapy in patients with differentiated #ThyroidCancer (DTC) wit….
0
1
0
RT @anantm: 🚨 New pub alert in Eur J of Cancer🚨.We introduce VISTA, an AI-virtual staining tool transforming H&E to IHC to detect M2-TAMs i….
0
4
0
RT @anantm: In @eBioMedicine we present SMuRF, a Swin Transformer-based model for fusing CT & HE slides to predict survival & tumor grade i….
0
2
0
INO-3107 DNA immunoRx induction of CD8+ HPV 6 & 11 T cell trafficking in #RRP another proof of principle in another #HPV related disease @InovioPharma @WinshipAtEmory @ucincinnati @JohnsHopkins. Source: Nature
nature.com
Nature Communications - In this phase 1/2 trial, the authors show that INO-3107, a DNA immunotherapy designed to elicit an immune response against HPV-6 and -11 recurrent respiratory...
0
0
1
RT @ASCO: We’ve issued new guidelines on the use of transoral robotic surgery in the treatment of oropharyngeal #SquamousCellCarcinoma: htt….
0
6
0
Sharing our recently published encouraging long term outcomes of Pembrolizumab and Cabozantinib in #RMHNSCC @WinshipAtEmory @MoffittNews
0
0
12
RT @WinshipAtEmory: 🎉Congrats to Winship researcher Canhua Xiao, PhD, RN, FAAN, on being awarded a $3.3M grant from @theNCI to study the ps….
0
1
0
Great to host @DrUppaluri at the @WinshipAtEmory Elkin lecture series; great talk and discussions around future IO applications in the peri OP #HNCA setting; @LesinskiLab @Chrystal_Paulos @NikkiSchmittMD
0
1
22
RT @AnwaarSaeed3: 😇 Excited for the Pittsburgh Annual Oncology Symposium this week! ✨ .Join us for updates on cutting edge cancer research,….
0
6
0
RT @AHNSinfo: New Post! Thank you to Dr. Michael Baddour, Head & Neck Surgeon at Emory University, who composed this expert review of the i….
0
8
0
RT @WinshipAtEmory: In an episode of the Backtable ENT (@_backtableENT) podcast, Winship otolaryngologist Nikki Schmitt, MD, FACS discusses….
backtable.com
Listen to the BackTable ENT Podcast on Understanding Drug Repurposing in Head & Neck Cancer with Dr. Nicole Schmitt. Visit BackTable.com.
0
4
0
Finally, the first positive trial of immunotherapy in the definitive Rx of mucosal LA # HNCA; look forward to more practice changing IO studies.
0
3
19
Happy to share Re irradiation Therapy With Nivolumab for Head and Neck Cancer @ShlomoKoyfmanMD @WinshipAtEmory @ClevelandClinic @MedicalCollege @StokedStokes @markmcdonaldmd @JamesBatesMD @JillRemickMD @soumon_rudra @ConorSteuerMD .
jamanetwork.com
This nonrandomized controlled trial assessed the benefits and toxic effects of intensity-modulated reirradiation therapy with nivolumab in the treatment of patients with recurrent or second primary...
0
10
29